Project Grant R41CA306678
Award Date 9/18/25
Completion Date 8/31/26
Dollars Obligated $398K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to Nanocan Therapeutics Corporation in collaboration with Johns Hopkins University, will fund the development and first clinical trial of an innovative Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel technology. The $998,781 award, with a project period from September 2025 to November 2026, aims to extend the use of local radiotherapy from palliative to potential distant...
- This $406,500 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel intratumoral delivery system by Absco Therapeutics, Inc. (Abscotx) to enhance solid tumor immunotherapy. The Oncolymer platform utilizes a thermoresponsive hydrogel and FDA-approved imaging agent to enable sustained, localized delivery of therapeutic agents like immune-sensitizing siRNA and the TLR7 agonist imiquimod. Preclinical studies have...
- This $306,265 federal Project Grant, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on September 16, 2025, will fund the preclinical development of VAX024 - a novel, second-generation recombinant bacterial minicell-based targeted oncolytic in situ immunization (ISI) agent. VAX024 is designed to overcome limitations of current oncolytic viral therapies by leveraging the grantee's proprietary delivery technology to generate a sterile, user-friendly oncolytic...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,253,869 to Celdara Medical, LLC to develop CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The funding supports advancing CM-HZ01 to the Investigational New Drug (IND) application stage, with the goal of providing a best-in-class immunotherapy for patients with limited effective treatment options for this deadly form of skin cancer. The project...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Glytr Therapeutics, Inc. to maximize the effectiveness of their pan-cancer immunotherapy platform based on Glycan-dependent T cell Recruiter (GLYTR) technologies. The $463,510 award, granted on September 10, 2025, supports research to enhance the target density and broaden the applicability of GLYTR1 bi-specific antibodies and GLYTR2 chimeric antigen receptor (CAR)...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $276,544 Project Grant to Ioncologi Inc. on September 1, 2025. The grant supports the development of IOI7, an autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cell (HSC) therapy, for the treatment of immune checkpoint inhibitor-resistant glioblastoma. The key objectives are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2) validate HSC...
- This $386,279 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop a microfluidic device for personalized immunotherapy screening on core needle biopsies from cancer patients. The project will: Create a "core needle biopsy" microfluidic cassette and protocols for functional immune assays, and Validate the microfluidic approach for screening immune checkpoint blockade therapy using core needle biopsies from...
- The Project Grant award of $424,734 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of a novel spatial proteomics approach to profile immune cell types and their locations within a tumor microenvironment. The University of Illinois, the awardee, aims to integrate 3D microscopy techniques with bottom-up proteomic assays to offer deep proteome profiles of specific immune cells at various subregions of a mouse tumor (Aims 1 and 2). The goal is...
- This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...